Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2012 by Beijing Chao Yang Hospital.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Ministry of Science and Technology of the People´s Republic of China
Information provided by (Responsible Party):
Chen WANG, Beijing Chao Yang Hospital
ClinicalTrials.gov Identifier:
NCT01531829
First received: February 9, 2012
Last updated: February 11, 2012
Last verified: February 2012
  Purpose

In selected patients with acute pulmonary embolism(PE), low dose (50mg/2h) recombinant tissue plasminogen activator (rt-PA) regimen had been reported to have less bleeding tendency than the FDA-approved rt-PA 100mg/2h regimen 100mg/2h regimen (3% vs.10%), it is worthwhile to reveal whether low dose rt-PA plus low molecular weight heparin (LMWH) can rapidly reverses RV pressure overload in PE, but not increase bleeding and other adverse events. The aim of the study is to compare thrombolytic treatment with LMWH in patients with acute normotensive PE with right ventricular dysfunction(RVD).


Condition Intervention Phase
Pulmonary Thromboembolisms
Pulmonary Embolism
Drug: Recombinant tissue plasminogen activator (rt-PA)
Drug: Low Molecular Weight Heparin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Low Dose Rt-PA Plus LMWH Compared With LMWH Alone for the Treatment of Normotensive Pulmonary Embolism Patients With Acute RV Dysfunction: A Randomized,Multi-Center,Controlled Trial

Resource links provided by NLM:


Further study details as provided by Beijing Chao Yang Hospital:

Primary Outcome Measures:
  • the composite end point of death from any cause or treatment failure,recurrence of VTE [ Time Frame: 7 days ] [ Designated as safety issue: No ]
  • improvements of right ventricular functions on echocardiogram and pulmonary artery obstruction on CT angiographs [ Time Frame: 7 days ] [ Designated as safety issue: No ]
  • serious life threatening bleeding such as cerebral hemorrhage and other major bleeding episodes [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]
  • clinical relevant non-major bleedings [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • the composite end point of death from any cause or treatment failure,recurrence of VTE [ Time Frame: 3 months and 6 months ] [ Designated as safety issue: No ]
  • improvements of right ventricular functions on echocardiogram and pulmonary artery obstruction on CT angiographs [ Time Frame: 3 months and 6 months ] [ Designated as safety issue: No ]
  • serious life threatening bleeding such as cerebral hemorrhage and other major bleeding episodes [ Time Frame: 3 months and 6 months ] [ Designated as safety issue: Yes ]
  • clinical relevant non-major bleedings [ Time Frame: 3 months and 6 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 460
Study Start Date: July 2009
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Low dose (50mg/2h) rt-PA plus LMWH
Low dose (50mg/2h) recombinant tissue plasminogen activator (rt-PA) plus low molecular weight heparin(LMWH)regimen
Drug: Recombinant tissue plasminogen activator (rt-PA)
Low dose (50mg/2h) rt-PA plus LMWH
Other Name: rt-PA
Active Comparator: LMWH
Low molecular weight heparin
Drug: Low Molecular Weight Heparin
0.1ml/10kg,q12h,5-7 days
Other Name: Nadroparin

Detailed Description:

In acute pulmonary embolism (PE), normotensive patients with acute RV dysfunction on echocardiography or computed tomography and with myocardial troponin elevation may have an adverse outcome. Thrombolysis rapidly reverses RV pressure overload in PE, but it increases the possibility of bleeding and it remains unclear whether it may improve the early or long-term clinical outcome of these selected normotensive patients.

In our previous study, we found that low dose (50mg/2h) recombinant tissue plasminogen activator (rt-PA) regimen had less bleeding tendency than the 100mg/2h regimen (3% vs.10%), it is worthwhile to reveal whether low dose rt-PA plus Low Molecular Weight Heparin (LMWH) can rapidly reverses RV pressure overload in PE, but not increase bleeding and other adverse events.

In this prospective, multicenter, randomized, control study, we compare low dose rt-PA plus LMWH vs. LMWH alone in acute normotensive pulmonary embolism patients with RV dysfunction. The primary efficacy outcome is the composite of death from any cause or treatment failure, improvements of right ventricular functions on echocardiogram and pulmonary artery obstruction on CT angiographs within 7 days of randomization. Second efficacy outcome is the recurrence of pulmonary embolism and deep venous thrombosis. Safety outcomes include serious life threatening bleeding such as cerebral hemorrhage and other major bleeding episodes, also include mild bleeding. In addition, 90-day clinical and echocardiographic follow-up will be performed, the recurrence of pulmonary embolism and deep venous thrombosis will be recorded. The study is expected to enroll approximately 460 patients.

By determining the benefits vs risks of Low dose rt-PA plus LMWH compared with LMWH alone for the treatment in submassive or intermediate-risk PE, this trial is expected to reveal the worth of Low dose rt-PA plus LMWH treatment and what kind of PE patients are suitable for thrombolysis.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. 18 y≤Age≤75y
  2. Acute PE (first symptoms occurred 14 d or less before randomization) confirmed by lung scan, or a positive computed tomographic pulmonary angiogram, or a positive selective pulmonary angiogram
  3. Hemodynamic stability, diastolic pressure>90mmHg.
  4. RV dysfunction confirmed by echocardiography (≥1 criterion), except left-side heart disease, congenital heart disease and mitral valve disease.

    • Increase of the right ventricle showed presented with RV end-diastolic anteroposterior diameter >25 mm, Right/left ventricular end-diastolic diameter >1 (apical or subcostal 4-chamber view) or Right/left ventricular end-diastolic anteroposterior diameter >0.5
    • Hypokinesis of RV-free wall (range of motion less than 5 mm)
    • Tricuspid regurgitation pressure >30mmHg

Exclusion Criteria:

  1. RV anterior wall thickness > 5mm confirmed by echocardiography
  2. Active internal bleeding and spontaneous intracranial hemorrhage in preceding 6 months
  3. Major surgery, organ biopsy or non-compressible punctures within 2 weeks
  4. Ischemic stroke occurred within 2 months
  5. Gastrointestinal bleeding within 10 days
  6. Severe trauma occurred within15 days
  7. Neurosurgery or eye surgery within 1 months
  8. Severe hypertension difficult to control (systolic blood pressure>180mmHg or diastolic blood pressure>110mmHg)
  9. Cardiopulmonary resuscitation
  10. Platelet count less than 100×109 / L
  11. Pregnancy, or within 2 week post partum
  12. Infective endocarditis; left atrial thrombus; aneurysm
  13. Serious liver and kidney dysfunction
  14. Diabetic hemorrhagic retinopathy
  15. Suffering with bleeding disorders
  16. Chronic thromboembolic pulmonary hypertension
  17. Moderate to severe chronic obstructive pulmonary disease (COPD).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01531829

Contacts
Contact: Chen Wang, PhD,MD 8610-85231893 cyh-birm@263.net
Contact: Tuguang Kuang, PhD,MD 8610-85231451 ktg2004@sina.com

  Show 35 Study Locations
Sponsors and Collaborators
Beijing Chao Yang Hospital
Ministry of Science and Technology of the People´s Republic of China
Investigators
Principal Investigator: Chen Wang, PhD,MD Beijing Chao Yang Hospital
  More Information

No publications provided

Responsible Party: Chen WANG, Professor of respiratory and critical care medicine, Beijing Chao Yang Hospital
ClinicalTrials.gov Identifier: NCT01531829     History of Changes
Other Study ID Numbers: BJCYH1893
Study First Received: February 9, 2012
Last Updated: February 11, 2012
Health Authority: China: Ministry of Science and Technology

Keywords provided by Beijing Chao Yang Hospital:
pulmonary embolism
right ventricular dysfunction
Thrombolysis
Heparin

Additional relevant MeSH terms:
Embolism
Pulmonary Embolism
Thromboembolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Thrombosis
Calcium heparin
Heparin
Heparin, Low-Molecular-Weight
Dalteparin
Plasminogen
Tissue Plasminogen Activator
Anticoagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Cardiovascular Agents

ClinicalTrials.gov processed this record on July 24, 2014